Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat
Retrieved on:
Sunday, November 15, 2020
Health, Consumer, Infectious diseases, Children, Pharmaceutical, Biotechnology, Medical specialties, Hepatology, Branches of biology, Clinical medicine, Digestive system, Bile acid, Enterohepatic circulation, Cholesterol, Bile, Ileal sodium/bile acid cotransporter, Bile acid sequestrant, the ITCH and IMAGINE II study, Alagille Syndrome, Maralixibat, Mirum Pharmaceuticals
Maralixibat, an apical sodium bile acid transporter (ASBT) inhibitor, has previously been shown to interrupt the enterohepatic circulation of bile acids, reducing pruritus .
Key Points:
- Maralixibat, an apical sodium bile acid transporter (ASBT) inhibitor, has previously been shown to interrupt the enterohepatic circulation of bile acids, reducing pruritus .
- Maralixibat treatment improved quality of life and led to improved growth parameters.
- To view the presentation and the complete data, please visit the AASLD section within the Events page on Mirums website.
- Children receiving maralixibat in the studies also demonstrated improvements in biomarkers of disease, including reductions in cholesterol and bile acid levels.